Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.
Kissling E, Hooiveld M, Sandonis Martín V, Martínez-Baz I, William N, Vilcu AM, Mazagatos C, Domegan L, de Lusignan S, Meijer A, Machado A, Brytting M, Casado I, Murray JK, Belhillil S, Larrauri A, O'Donnell J, Tsang R, de Lange M, Rodrigues AP, Riess M, Castilla J, Hamilton M, Falchi A, Pozo F, Dunford L, Cogdale J, Jansen T, Guiomar R, Enkirch T, Burgui C, Sigerson D, Blanchon T, Martínez Ochoa EM, Connell J, Ellis J, van Gageldonk-Lafeber R, Kislaya I, Rose AM, Valenciano M; I-MOVE-COVID-19 primary care study team; I-MOVE-COVID-19 primary care study team (in addition to authors above). Kissling E, et al. Among authors: william n. Euro Surveill. 2021 Jul;26(29):2100670. doi: 10.2807/1560-7917.ES.2021.26.29.2100670. Euro Surveill. 2021. PMID: 34296676 Free PMC article.
Moving epidemic method (MEM) applied to virology data as a novel real time tool to predict peak in seasonal influenza healthcare utilisation. The Scottish experience of the 2017/18 season to date.
Murray JLK, Marques DFP, Cameron RL, Potts A, Bishop J, von Wissmann B, William N, Reynolds AJ, Robertson C, McMenamin J. Murray JLK, et al. Among authors: william n. Euro Surveill. 2018 Mar;23(11):18-00079. doi: 10.2807/1560-7917.ES.2018.23.11.18-00079. Euro Surveill. 2018. PMID: 29560854 Free PMC article.
Absence of association between 2019-20 influenza vaccination and COVID-19: Results of the European I-MOVE-COVID-19 primary care project, March-August 2020.
Kissling E, Hooiveld M, Brytting M, Vilcu AM, de Lange M, Martínez-Baz I, Sigerson D, Enkirch T, Belhillil S, Meijer A, Castilla J, William N, Carnahan A, Falchi A, Hendriksen J, Casado I, Murray J, Enouf V, Dijkstra F, Marques DFP, Valenciano M. Kissling E, et al. Among authors: william n. Influenza Other Respir Viruses. 2021 Jul;15(4):429-438. doi: 10.1111/irv.12839. Epub 2021 Jan 22. Influenza Other Respir Viruses. 2021. PMID: 33481344 Free PMC article.
Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021.
Kissling E, Hooiveld M, Martínez-Baz I, Mazagatos C, William N, Vilcu AM, Kooijman MN, Ilić M, Domegan L, Machado A, de Lusignan S, Lazar M, Meijer A, Brytting M, Casado I, Larrauri A, Murray JK, Behillil S, de Gier B, Mlinarić I, O'Donnell J, Rodrigues AP, Tsang R, Timnea O, de Lange M, Riess M, Castilla J, Pozo F, Hamilton M, Falchi A, Knol MJ, Kurečić Filipović S, Dunford L, Guiomar R, Cogdale J, Cherciu C, Jansen T, Enkirch T, Basile L, Connell J, Gomez V, Sandonis Martín V, Bacci S, Rose AM, Pastore Celentano L, Valenciano M; I-MOVE-COVID-19 and ECDC primary care study teams; I-MOVE-COVID-19 and ECDC primary care study team (in addition to authors above). Kissling E, et al. Among authors: william n. Euro Surveill. 2022 May;27(21):2101104. doi: 10.2807/1560-7917.ES.2022.27.21.2101104. Euro Surveill. 2022. PMID: 35620997 Free PMC article.
Excess mortality in Europe coincides with peaks of COVID-19, influenza and respiratory syncytial virus (RSV), November 2023 to February 2024.
Nørgaard SK, Nielsen J, Nordholm AC, Richter L, Chalupka A, Sierra NB, Braeye T, Athanasiadou M, Lytras T, Denissov G, Luomala O, Fouillet A, Pontais I, An der Heiden M, Zacher B, Weigel A, Foppa I, Gkolfinopoulou K, Panagoulias I, Paldy A, Malnasi T, Domegan L, Kelly E, Rotem N, Rakhlin O, de'Donato FK, Di Blasi C, Hoffmann P, Velez T, England K, Calleja N, van Asten L, Jongenotter F, Rodrigues AP, Silva S, Klepac P, Gomez-Barroso D, Gomez IL, Galanis I, Farah A, Weitkunat R, Fehst K, Andrews N, Clare T, Bradley DT, O'Doherty MG, William N, Hamilton M, Søborg B, Krause TG, Bundle N, Vestergaard LS. Nørgaard SK, et al. Among authors: william n. Euro Surveill. 2024 Apr;29(15):2400178. doi: 10.2807/1560-7917.ES.2024.29.15.2400178. Euro Surveill. 2024. PMID: 38606570 Free PMC article.
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Köhn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Leyssen M, Greenwood B, Douoguih M, Leigh B, Watson-Jones D; EBL3001 study group. Ishola D, et al. Lancet Infect Dis. 2022 Jan;22(1):97-109. doi: 10.1016/S1473-3099(21)00125-0. Epub 2021 Sep 13. Lancet Infect Dis. 2022. PMID: 34529963 Free PMC article. Clinical Trial.
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Köhn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Greenwood B, Leyssen M, Douoguih M, Leigh B, Watson-Jones D; EBL3001 study group. Afolabi MO, et al. Lancet Infect Dis. 2022 Jan;22(1):110-122. doi: 10.1016/S1473-3099(21)00128-6. Epub 2021 Sep 13. Lancet Infect Dis. 2022. PMID: 34529962 Free PMC article. Clinical Trial.
De novo variants in GABRA4 are associated with a neurological phenotype including developmental delay, behavioral abnormalities and epilepsy.
Sajan SA, Gradisch R, Vogel FD, Coffey AJ, Salyakina D, Soler D, Jayakar P, Jayakar A, Bianconi SE, Cooper AH, Liu S, William N, Benkel-Herrenbrück I, Maiwald R, Heller C, Biskup S, Leiz S, Westphal DS, Wagner M, Clarke A, Stockner T, Ernst M, Kesari A, Krenn M. Sajan SA, et al. Among authors: william n. Eur J Hum Genet. 2024 Apr 2. doi: 10.1038/s41431-024-01600-3. Online ahead of print. Eur J Hum Genet. 2024. PMID: 38565639
48 results